Soligenix Inc (SNGX)

$0.40 +0.02 (4.93%)
Market Cap 5.65M
Revenue (ttm) 0.00
Net Income (ttm) -11.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,800
Avg Vol 744,280
Day's Range N/A - N/A
Shares Out 14.82M
Stochastic %K 78%
Beta 1.93
Analysts Strong Buy
Price Target $1.38

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology th...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 538 8200
Fax: 609 452 6467
Address:
29 Emmons Drive, Suite B-10, Princeton, United States
splendor
splendor Aug. 19 at 11:03 AM
$MRNA wow that looks amazing Can imagin whats will happen to $SNGX when the cepi fund coming
0 · Reply
splendor
splendor Aug. 19 at 10:57 AM
$MRNA wow Come to $SNGX A big find will coming soon Vaccine to ebola
0 · Reply
csabuus
csabuus Aug. 18 at 7:17 PM
$SNGX lwts go to 1
0 · Reply
DrLotto
DrLotto Aug. 18 at 7:15 PM
$SNGX Guys, if CEPI approves ThermoVax, which price can it hit? Any suggestions?
2 · Reply
JK1033
JK1033 Aug. 18 at 5:21 PM
$SNGX Typical Review Window: Major global health agencies like the Coalition for Epidemic Preparedness Innovations (CEPI) and BARDA typically run a multi-stage review process that takes 3 to 6 months from application to formal public announcement.SNGX Estimated Catalyst Date: Because Soligenix formally submitted its vaccine development funding application for the Bundibugyo Ebola vaccine program in June 2026, a decision or update from CEPI is highly anticipated between September 2026 and December 2026.
1 · Reply
JK1033
JK1033 Aug. 18 at 5:20 PM
$SNGX Soligenix is locked in a tight race against time. The December 7, 2026 Nasdaq compliance deadline sits right at the end of the expected window for their CEPI grant decision.If CEPI approves the grant before December, a massive spike in positive sentiment could push SNGX organically over $1.00, rendering a split unnecessary. If the decision is delayed or rejected, a sixth historical reverse stock split is highly probable before the year ends to prevent delisting
0 · Reply
DrLotto
DrLotto Aug. 18 at 10:28 AM
$SNGX 0.46-0.5 + Today
1 · Reply
UWanSum
UWanSum Aug. 18 at 10:09 AM
$SNGX this thing finally waking up?
0 · Reply
DrLotto
DrLotto Aug. 18 at 10:06 AM
$SNGX market cap only 8m.
0 · Reply
DrLotto
DrLotto Aug. 17 at 4:12 PM
$SNGX Looks Like these two gaps to be closed . Next target 0.70+
0 · Reply
Latest News on SNGX
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Aug 7, 2026, 7:30 AM EDT - 12 days ago

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

SNGX

Soligenix Quarterly report: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 12 days ago

Soligenix Quarterly report: Q2 2026

Soligenix Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Soligenix Proxy statement: Proxy filing

Soligenix Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 16 days ago

Soligenix Proxy statement: Proxy filing

Soligenix Proxy statement: Proxy filing

Jul 23, 2026, 8:00 AM EDT - 27 days ago

Soligenix Proxy statement: Proxy filing

Soligenix Proxy statement: Proxy filing

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Soligenix Proxy statement: Proxy filing

Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine

2026-06-08T11:45:52.000Z - 2 months ago

Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine

SNGX

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGX

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026, 7:30 AM EDT - 3 months ago

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGX

Soligenix reports Q1 EPS (28c) vs. (97c) last year

2026-05-08T12:43:19.000Z - 3 months ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year

SNGX

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SNGX

Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Quarterly report: Q1 2026

Soligenix Earnings release: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Earnings release: Q1 2026

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-05-04T11:16:01.000Z - 3 months ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

SNGX

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

2026-04-28T12:08:02.000Z - 4 months ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

SNGX

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

SNGX

Soligenix Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Soligenix Slides: Corporate presentation

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

2026-04-02T12:03:59.000Z - 4 months ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

SNGX

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Apr 2, 2026, 7:30 AM EDT - 4 months ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

SNGX

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 31, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

SNGX

Soligenix Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Soligenix Annual report: Q4 2025

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

2026-03-26T11:36:24.000Z - 5 months ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

SNGX

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 26, 2026, 7:30 AM EDT - 5 months ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

SNGX

Soligenix Slides: Corporate presentation

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 23, 2026, 7:30 AM EDT - 5 months ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

SNGX

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

Mar 19, 2026, 8:00 AM EDT - 5 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

SNGX

Soligenix announces HyBryte clinical summary published

2026-03-19T11:36:43.000Z - 5 months ago

Soligenix announces HyBryte clinical summary published

SNGX

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

SNGX

Soligenix Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

Soligenix says SGX945 granted PIM designation in UK by MHRA

2026-03-10T11:42:32.000Z - 5 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

SNGX

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

SNGX

Soligenix receives positive opinion from EMA for OOD request for dusquetide

2026-02-26T13:00:59.000Z - 6 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

SNGX

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 26, 2026, 7:30 AM EST - 6 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

SNGX

Soligenix to Present at BIO Investment & Growth Summit

Feb 24, 2026, 7:30 AM EST - 6 months ago

Soligenix to Present at BIO Investment & Growth Summit

SNGX

Soligenix Details Recent Progress and Upcoming Milestones

Feb 12, 2026, 7:30 AM EST - 6 months ago

Soligenix Details Recent Progress and Upcoming Milestones

SNGX

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

2025-12-18T12:41:21.000Z - 8 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

SNGX

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 8 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

SNGX

Soligenix announces results from Phase 2a trial of SGX302

2025-12-17T12:36:34.000Z - 8 months ago

Soligenix announces results from Phase 2a trial of SGX302

SNGX

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 17, 2025, 7:30 AM EST - 8 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

SNGX

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Dec 3, 2025, 8:30 AM EST - 9 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

SNGX

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

2025-11-19T12:35:43.000Z - 9 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

SNGX

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 19, 2025, 7:30 AM EST - 9 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

SNGX

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:30 AM EST - 10 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

SNGX

Soligenix Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Soligenix Quarterly report: Q3 2025

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 14, 2025, 7:30 AM EDT - 11 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

SNGX

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

2025-10-07T11:35:32.000Z - 11 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

SNGX

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 11 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

SNGX

Soligenix expands European Medical Advisory Board for CTCL

2025-09-30T11:35:29.000Z - 11 months ago

Soligenix expands European Medical Advisory Board for CTCL

SNGX

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

SNGX

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

SNGX

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 11 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

SNGX

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 23, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

SNGX

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

2025-09-19T21:05:11.000Z - 11 months ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

SNGX

Soligenix Registration statement: Registration Filing

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Soligenix Registration statement: Registration Filing

Soligenix Slides: Corporate Presentation

Sep 19, 2025, 7:00 AM EDT - 11 months ago

Soligenix Slides: Corporate Presentation

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

2025-09-04T11:35:46.000Z - 1 year ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

SNGX

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

SNGX

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SNGX

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

2025-08-18T11:35:27.000Z - 1 year ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

SNGX

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 18, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

SNGX

Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q2 2025

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

SNGX

Soligenix receives FDA orphan designation for dusquetide

2025-08-13T22:00:32.000Z - 1 year ago

Soligenix receives FDA orphan designation for dusquetide

SNGX

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Aug 8, 2025, 8:30 AM EDT - 1 year ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

SNGX

Soligenix’s SGX945 shows efficacy in Phase 2 Behcet’s Disease trial

2025-07-31T12:01:56.000Z - 1 year ago

Soligenix’s SGX945 shows efficacy in Phase 2 Behcet’s Disease trial

SNGX

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

SNGX

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

SNGX

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

SNGX

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

SNGX

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

SNGX

Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025

Soligenix Earnings release: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

SNGX

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

SNGX

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

SNGX

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

SNGX

Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024

Soligenix Earnings release: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

SNGX

Soligenix to Present at BIO CEO & Investor Conference

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

SNGX

Soligenix to Present at Upcoming Investor Conferences

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

SNGX

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

SNGX

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

SNGX

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

SNGX

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

SNGX

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

SNGX

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

SNGX

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

SNGX

splendor
splendor Aug. 19 at 11:03 AM
$MRNA wow that looks amazing Can imagin whats will happen to $SNGX when the cepi fund coming
0 · Reply
splendor
splendor Aug. 19 at 10:57 AM
$MRNA wow Come to $SNGX A big find will coming soon Vaccine to ebola
0 · Reply
csabuus
csabuus Aug. 18 at 7:17 PM
$SNGX lwts go to 1
0 · Reply
DrLotto
DrLotto Aug. 18 at 7:15 PM
$SNGX Guys, if CEPI approves ThermoVax, which price can it hit? Any suggestions?
2 · Reply
JK1033
JK1033 Aug. 18 at 5:21 PM
$SNGX Typical Review Window: Major global health agencies like the Coalition for Epidemic Preparedness Innovations (CEPI) and BARDA typically run a multi-stage review process that takes 3 to 6 months from application to formal public announcement.SNGX Estimated Catalyst Date: Because Soligenix formally submitted its vaccine development funding application for the Bundibugyo Ebola vaccine program in June 2026, a decision or update from CEPI is highly anticipated between September 2026 and December 2026.
1 · Reply
JK1033
JK1033 Aug. 18 at 5:20 PM
$SNGX Soligenix is locked in a tight race against time. The December 7, 2026 Nasdaq compliance deadline sits right at the end of the expected window for their CEPI grant decision.If CEPI approves the grant before December, a massive spike in positive sentiment could push SNGX organically over $1.00, rendering a split unnecessary. If the decision is delayed or rejected, a sixth historical reverse stock split is highly probable before the year ends to prevent delisting
0 · Reply
DrLotto
DrLotto Aug. 18 at 10:28 AM
$SNGX 0.46-0.5 + Today
1 · Reply
UWanSum
UWanSum Aug. 18 at 10:09 AM
$SNGX this thing finally waking up?
0 · Reply
DrLotto
DrLotto Aug. 18 at 10:06 AM
$SNGX market cap only 8m.
0 · Reply
DrLotto
DrLotto Aug. 17 at 4:12 PM
$SNGX Looks Like these two gaps to be closed . Next target 0.70+
0 · Reply
GreedyGopher
GreedyGopher Aug. 17 at 2:52 PM
$SNGX Reminder......, 4 reverse splits, never brought ANYTHING to market and never will....
0 · Reply
DrLotto
DrLotto Aug. 17 at 2:10 PM
$SNGX guys, what is your average?
1 · Reply
splendor
splendor Aug. 17 at 10:57 AM
$SNGX come back to 1$ Before the cepi fund
0 · Reply
DrLotto
DrLotto Aug. 17 at 10:41 AM
$SNGX 0.5+ Today
0 · Reply
DrLotto
DrLotto Aug. 17 at 9:02 AM
$SNGX adding here
0 · Reply
DrLotto
DrLotto Aug. 15 at 7:56 PM
$SNGX
0 · Reply
DrLotto
DrLotto Aug. 15 at 7:34 PM
$SNGX
1 · Reply
DrLotto
DrLotto Aug. 15 at 12:11 PM
$SNGX try to use on this stock: https://youtube.com/shorts/igAiv5Zr5Lw
0 · Reply
DrLotto
DrLotto Aug. 15 at 8:06 AM
$SNGX Guys, place your orders with desired limit. If any action happens in premarket, be ready to unload)))
1 · Reply
DrLotto
DrLotto Aug. 14 at 8:26 PM
$SNGX Unbelievable: this stock is still alive: I did invest a few years ago did some small profits some losses. I bought a small position: lottery ticket
0 · Reply
DonaldDuckBatman
DonaldDuckBatman Aug. 14 at 2:46 PM
$MDXH $RCT $SNGX
0 · Reply
splendor
splendor Aug. 14 at 6:17 AM
$SNGX Production and access to the vaccines, if sufficient efficacy data would arise, would also need to be facilitated at scale and made available to the affected populations, WHO said. https://www.globaltimes.cn/page/202608/1368147.shtml
1 · Reply